Xue Kefan, Li Yihan, Hu Rui, Hu Xiao, Guo Ran, Guo Hongxia, Li Gang
Division of Cardiology, Institute of Geriatric Diseases, Hebei General Hospital, Shijiazhuang, Hebei 050000, P.R. China.
Graduate School of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.
Exp Ther Med. 2025 Apr 30;29(6):126. doi: 10.3892/etm.2025.12876. eCollection 2025 Jun.
The incidence of coronary atherosclerotic heart disease is on the rise, posing a serious threat to public health. Emerging evidence highlights the interplay between systemic inflammation and cardiovascular pathophysiology, suggesting novel diagnostic avenues. The aim of the present study was to evaluate the predictive value of fecal sulfatide and neutrophil-to-lymphocyte ratio (NLR), both individually and in combination, for coronary heart disease (CHD). A total of 523 patients diagnosed with CHD at the Cardiovascular Department of Hebei General Hospital (Shijiazhuang, China) from August 2022 to September 2023 were included in the experimental group, along with 198 healthy controls. The CHD group was further subdivided into stable angina pectoris (n=194), unstable angina pectoris (n=134), and acute myocardial infarction (AMI) groups (n=195). Fecal sulfatide and serum NLR levels were measured in both the experimental and control groups, as well as within each CHD subgroup. Multivariate logistic regression was utilized to assess whether these biomarkers serve as independent risk factors for CHD. The predictive value of fecal sulfatide and serum NLR was evaluated using receiver operating characteristic curves. Fecal sulfatide and serum NLR levels were distinctly higher in the CHD group compared with the control group (2.40±0.48 vs. 1.64±0.39 µmol/l and 2.92 vs. 1.65; P<0.05). Patients with AMI had higher NLR levels than those with stable and unstable angina pectoris (5.55 vs. 2.65 and 2.68; P<0.05). Fecal sulfatide levels were also elevated in patients with AMI (2.50±0.44 µmol/l) compared with patients with stable angina pectoris (2.32±0.48 µmol/l). Both fecal sulfatide (AUC=0.899) and NLR (AUC=0.811) exhibited strong predictive accuracy for CHD. When combined, the predictive value (AUC=0.945) was further improved. Elevated levels of fecal sulfatide and serum NLR in patients with CHD revealed that these biomarkers may serve as valuable adjuncts in the diagnosis of CHD. The combined use of these biomarkers enhances the accuracy and reliability of CHD prediction.
冠状动脉粥样硬化性心脏病的发病率呈上升趋势，对公众健康构成严重威胁。新出现的证据突出了全身炎症与心血管病理生理学之间的相互作用，提示了新的诊断途径。本研究的目的是评估粪便硫苷脂和中性粒细胞与淋巴细胞比值（NLR）单独及联合对冠心病（CHD）的预测价值。2022年8月至2023年9月在河北医科大学第一医院（中国石家庄）心血管内科诊断为CHD的523例患者纳入实验组，同时纳入198例健康对照。CHD组进一步细分为稳定型心绞痛组（n = 194）、不稳定型心绞痛组（n = 134）和急性心肌梗死（AMI）组（n = 195）。在实验组和对照组以及每个CHD亚组中测量粪便硫苷脂和血清NLR水平。采用多因素logistic回归评估这些生物标志物是否为CHD的独立危险因素。使用受试者工作特征曲线评估粪便硫苷脂和血清NLR的预测价值。CHD组粪便硫苷脂和血清NLR水平明显高于对照组（2.40±0.48 vs. 1.64±0.39 μmol/l和2.92 vs. 1.65；P<0.05）。AMI患者的NLR水平高于稳定型和不稳定型心绞痛患者（5.55 vs. 2.65和2.68；P<0.05）。与稳定型心绞痛患者（2.32±0.48 μmol/l）相比，AMI患者的粪便硫苷脂水平也升高（2.50±0.44 μmol/l）。粪便硫苷脂（AUC = 0.899）和NLR（AUC = 0.811）对CHD均表现出较强的预测准确性。联合使用时，预测价值（AUC = 0.945）进一步提高。CHD患者粪便硫苷脂和血清NLR水平升高表明，这些生物标志物可能是CHD诊断中有价值的辅助指标。联合使用这些生物标志物可提高CHD预测的准确性和可靠性。
